Qiagen and Eli Lilly Collaborate on New IVD Test for Alzheimer’s Detection
Qiagen and Eli Lilly partner to develop a diagnostic test for detecting Alzheimer's APOE genotypes.
Qiagen has teamed up with Eli Lilly to develop an innovative
in vitro diagnostic (IVD) test that detects apolipoprotein E (APOE) genotypes.
This test, designed for diagnosing Alzheimer's disease, will be integrated into
Qiagen's QIAstat-Dx platform and will detect three APOE genotypes: APOE2,
APOE3, and APOE4.
The APOE4 genotype is linked to an increased risk of
early-onset Alzheimer’s, and individuals carrying two copies of the APOE4 gene
face an even higher risk of developing the disease. Research shows that APOE
variants influence Alzheimer’s risk across age, sex, and ethnicity.
Currently, there are 76 Alzheimer’s diagnostic platforms in
development globally, with 10 undergoing clinical trials. Most of these tests
use tau proteins as biomarkers. Lilly also partnered with Roche to develop a
tau biomarker test that earned breakthrough FDA designation in April 2024,
highlighting its significance as a screening tool for Alzheimer's.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Novo Nordisk firma un acuerdo de $2.6B con Hengrui por un GLP-1 oral
Discussion